Answers are grounded in this paper and cite their sources.
BACKGROUND: The use of second-generation antipsychotics (SGAs) for managing challenging behaviors in youth with autism spectrum disorder (ASD) is increasing, but studies on antipsychotic-induced weight gain in this population remain limited. Overweight/obesity [body mass index (BMI) ≥85th percentile] could increase health complications and health care costs. This study examines clinical factors associated with overweight/obesity in youth with ASD. METHODS: Electronic medical records of youth (ages 5 to 17 years) with ASD, seen at a university-affiliated Autism Center from 2018 to 2022, were analyzed. RESULTS: There were 97 youths with ASD prescribed SGAs and 261 who were not. The rate of overweight/obesity (BMI≥85th percentile) did not differ by SGA use. Youth prescribed SGAs were more likely to have public insurance (63.9% vs. 45.2%, P =0.002) and a comorbid disruptive behavior disorder (DBD) diagnosis (69.1% vs. 24.1%, P <0.001). Youth with overweight/obesity were more likely to have public insurance (61.6% vs. 42.5%, P <0.001) and a DBD diagnosis (46.6% vs. 29.2%, P <0.001). Youth with SGAs and stimulants were less likely to be overweight or obese than youth with SGAs without stimulant co-treatment. CONCLUSIONS: Mean BMI percentile and the rate of overweight/obesity did not differ by SGA use. Public insurance and DBD diagnosis have positive relationships with overweight/obesity, whereas stimulant co-treatment with SGA had a negative relationship. It is important to carefully consider the risks and benefits of SGA use, especially in under-resourced youth and those with disruptive behaviors.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: